Clinical Report: Renal AL Amyloidosis Linked to Waldenström Macroglobulinemia
Overview
This report presents a case of renal AL amyloidosis in a patient with Waldenström macroglobulinemia (WM), highlighting the challenges in diagnosis and treatment. The patient achieved a partial hematologic response following treatment with bendamustine and rituximab but ultimately succumbed to a severe pulmonary infection.
Background
Waldenström macroglobulinemia is a rare B-cell lymphoma that can lead to various complications, including renal AL amyloidosis. This condition poses significant treatment challenges and can result in severe morbidity and mortality. Understanding the relationship between WM and renal complications is crucial for timely diagnosis and management.
Data Highlights
No numerical data available.
Key Findings
Renal AL amyloidosis is a rare but serious complication of Waldenström macroglobulinemia.
Patients with WM should be routinely tested for serum and urine monoclonal free light chains.
The bendamustine plus rituximab (BR) regimen can be an effective first-line treatment for WM patients with renal AL amyloidosis.
Close monitoring for treatment-related adverse effects, particularly severe infections, is essential during therapy.
Partial hematologic response can be achieved, as evidenced by a decrease in serum IgM levels and proteinuria.
Clinical Implications
Healthcare providers should maintain a high index of suspicion for renal involvement in patients with WM. Regular monitoring and proactive management of potential treatment-related complications are critical to improving patient outcomes.
Conclusion
This case underscores the importance of early detection and management of renal complications in WM, as well as the need for careful monitoring during treatment to mitigate risks of severe infections.
